Anti-human CD20 (Rituximab Biosimilar)

Amount: 100ug

Product Details

This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Rituximab, making it well-suited for research applications. It specifically binds to human CD20, a B cell-specific transmembrane protein (33–37 kDa) also known as B-lymphocyte antigen, B1, or Bp35. CD20 plays a key role in regulating intracellular calcium levels and promoting B cell activation, and it is essential for effective immune responses against T cell-independent antigens. CD20 expression begins during the transition from pre-B to immature B cells in the bone marrow, following the induction of CD19 and IgM. Its expression increases with B cell maturation and is found on nearly all mature B cells, but it is absent on plasma blasts and plasma cells. CD20 is commonly expressed in B cell malignancies and serves as an important diagnostic marker for B cell lymphomas and leukemias. Therapeutic anti-CD20 monoclonal antibodies, such as Rituximab, have been widely used to treat leukemias, lymphomas, and various autoimmune disorders. Rituximab exerts its effects through B cell depletion via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the targeted elimination of CD20-positive cells. This Rituximab biosimilar is validated for in vitro applications and is ideal for modeling CD20-targeted depletion and immune effector functions in research settings.

Specifications

Product name: Anti-human CD20 (Rituximab Biosimilar) Research Grade

Species: Human

Storage condition: 4°C for short term; -20°C for long term

Note: For research use only. Not suitable for human use

Isotype: IgG1

Clonality: Monoclonal Antibody

Purity: >95% Determined by SDS-PAGE

Sterility: 0.2 µm filtration

Purification: Protein A

RRID: AB_2894729

Molecular Weight: 150 kDa